Cerevance Media Center

Current News

November 13, 2023

Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease

Cerevance Doses First Patient in ASCEND Phase 2 Clinical Study of CVN424, a First-in-Class, Non-Dopaminergic Therapy for the Treatment of Parkinson’s Disease

READ FULL

September 19, 2023

Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease

Cerevance today announced that the first subject has been dosed in the Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of CVN293.

READ FULL

August 28, 2023

Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023

Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.

READ FULL

July 10, 2023

Cerevance to Present at the Alzheimers Association International Conference

Cerevance to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.

READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

May 20, 2024

Cerevance to Participate in Precision Neurotherapeutics Panel During the 2024 BIO International Convention

Date:
Tuesday, June 4, 2024
Time:
11 am – 12 pm, PT
Location:
San Diego, CA
Media:
Panel Discussion
Read full

May 9, 2024

Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders

Date:
Monday, May 20, 2024
Time:
9:35 – 10:20am
Location:
Lisbon, Portugal
Media:
Oral Presentation
Read full

April 29, 2024

Cerevance to Participate at Wells Fargo Virtual Private Biotech Symposium

Date:
Monday, May 6, 2024
Time:
Per meeting scheduling
Location:
Virtual
Media:
Scheduled Meetings
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

April 8, 2024

Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment

Bürli, R. W., Doyle,K. J., Dickson, L., Rowland, A., Matthews, K., Stott, A. J., Teall, M., Ossola, B., Russell, S. G., Harvey, J. R. M., Wu,Y., Narayana, L., Brice, N. L., Carlton, M., Dawson, L. A.

Viewview

March 15, 2024

Differential contribution of THIK‑1 K+ channels and P2X7 receptors to ATP‑mediated neuroinflammation by human microglia

Rifatm, A., Ossola, B., Bürli, R. W. , Dawson, L. A., Brice, N. L., Rowland, A., Lizio, M., Xu, X., Page, K., Fidzinski, P., Onken, J., Holtkamp, M., Heppner, F. L., Geiger, J. R. P., Madry, C.

Viewview

March 7, 2024

NETSseq reveals deep molecular insights into astrocyte biology and identifies novel therapeutic targets for Alzheimer’s disease

Xu, X., Bender, C., Harvey, J., Ugbode, C., Ossola, B., Barker, D., Powell, J., Cadwalladr, D., Thompson, T., Lawrence, J., Sheardown, S., Crane, G., Page, K., Carlton, M., Brice, N., Dawson, L.

Viewview

February 12, 2024

Discovery and First-time Disclosure of CVN766, an Exquisitely Selective Orexin 1 Receptor Antagonist

Glen, A., Bürli, R.W., Livermore, D., Buffham, W., Merison, S., Rowland, A.E., Newman, R., Fieldhouse, C., Miller, D.J., Dawson, L.A., Matthews, K., Carlton, M.B., Brice, N.L.

Viewview

December 25, 2023

NETSseq Advances the Understanding of Neuronal Vulnerability in AD Progression Facilitating the Identification of Novel Therapeutic Targets at the Single Cell Type Level

Bayraktar, G.,Christie, L., Brice, N., Xu, X., Stirparo, G., Lizio, M., Powell, J., Cadwalladr, D., Cheung, T., Sheardown, S., Page, K., Dawson, L.A.,Carlton, M.

Viewview

November 15, 2023

NETSseq Platform Identifies the Astrocyte Specific Potassium Channel KCNJ10 (kir4.1) as a Target for the Potential Treatment of Neurodegenerative Diseases

Bender, C.L., Harvey, J.R.M., Burley, R.,Ossola, B., Pickford, P.J., Barker, D.F., Mulligan, V.J., Page, K.J., Carlton, M.L.N, Brice, N.L., Dawson, L.A.

Viewview